Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes produce a strong configuration-dependent inhibition of the hormone sensitive MXT-mammary carcinoma of the mouse. Besides an interference in the DNA synthesis in analogy to cisplatin an estrogen level lowering effect is supposed to be the mode of action. The new complexes show also a significant activity on the hormone-independent MXT-mammary carcinoma of the mouse.
Schertl
S
S
Institut für Pharmazie, Lehrstuhl für Pharmazeutische Chemie II, Universität Regensburg, FRG.
Gust
R
R
Müller
R
R
Spruss
T
T
Schönenberger
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009944:Organoplatinum Compounds / Q000138:chemical synthesis* / Q000494:pharmacology; D013237:Stereoisomerism
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds